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LIST OF ABBREVIATIONS 
HBV --------- hepatitis B virus 
HB --------- hepatitis B 
HBsAg -------- hepatitis B surface antigen 
anti-HBs- ------ antibody to hepatitis B surface antigen 
HBeAg -------- hepatitis B e-antigen 
anti-HBe- ------ antibody to hepatitis B e-antigen 
e/anti-e- ------ e-antigen and antibody system 
HBeAg -------- hepatitis B core antigen 
anti-HBc- ------ antibody to hepatitis B core antigen 
PHA --------- passive hemagglutination assay 
RPHA -------- reversed passive hemagglutination assay 
RIA --------- radioimmunoassay 




The inhabitants of four islands in French Polynesia were studied for sero¬ 
logic evidence of HBV infection and in order to test the hypothesis that suscep¬ 
tibility to becoming chronically infected with HBV is subject to genetic de- 
terminents. 
Seventy percent of the inhabitants of the island of Hiva Oa and 74% of those 
living on Maiao were included in the study. They were estimated to be a sample 
■representative of the total population with the possible exception that children 
under ten years of age were underrepresented. 
Approximately 40% of the inhabitants of villages on two additional islands, 
Rapa and Mangareva, were also studied. It could not be estimated whether they 
were representative samples of their total populations. 
Prevalence of HBV infection was determined by measurement of its specific 
serologic markers, HBsAg, anti-HBs and anti-HBc. Distribution of these markers 
within the study populations was expressed in terms of age and sex. 
Two surveys separated in time by 19 months were conducted on the island 
of Maiao. This allowed for estimation of the incidence of HBV infection among 
susceptible persons and for a detailed pedigree analysis of the patterns of in¬ 
fection acquisition and distribution within families. Thus, evidence that genetic 
and/or environmental factors influenced host susceptibility to either the develop¬ 
ment or the maintenance of HBV infection could be considered. 
HBsAg prevalence and incidence (among susceptible individuals) was 20% 
on Maiao while the overall infection rate was 88%. HBsAg was found in 24% of 
males and 15% of females while infection (HBsAg plus anti-HBs plus anti-HBc) 
was 93% among males and 83% among females. In both sexes, HBsAg prevalence 
' 
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was greatest in the 30 - 39 year old age groups while overall infection was 
lowest (80% in males and 55% in females) in the 1 - 9 year old age group with 
a generally maintained increase thereafter, in the 90 to 100% range. This 
preponderance of males with HBsAg was similar to that found in many other 
populations throughout the world although the age of peak prevalence was some¬ 
what greater. The finding of the lowest prevalence (and the greatest number 
of susceptible individuals) in the youngest subjects is at variance with some 
other reports where HBsAg was most prevalent in these ages. This may reflect 
sampling differences between this study and others. 
A different situation was found to exist on the island of Hiva 0a where, 
although the overall infection (70%) and HBsAg prevalence(20%) rates were high, 
the prevalence of HBsAg among males (16%) was lower than that among females 
(24%) as was the infection rate (58% versus 73%). Neither HBsAg nor infection 
prevalence had a marked age-specific increase or decrease as was the case on 
Maiao, nor did those individuals acutely infected appear to be distributed by age 
as they were on Maiao. For these reasons it is suggested that the inhabitants 
of Hiva 0a, either for environmental or for genetic reasons, did 
not handle HBV infection in a manner similar to that observed on Maiao or in 
some other South Pacific populations. 
Pedigree analysis of the Maiao inhabitants was consistent with the operation 
of an autosomal recessive inheritance of susceptibility to becoming an HBsAg- 
positive chronic carrier after HBV infection. However, this mechanism could 
not be definitively ruled in or out. Other common modes of inheritance were 
seen not to operate. 
There was statistically significant evidence that all children, and 1 - 9 
. 
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year old children in particular, of an HBsAg-posifive mother were more likely to 
have HBsAg than those of any other parents (including fathers with HBsAg). However, 
infection per se was not significantly more likely to occur in progeny of a mother 
with HBsAg. 
Limited evidence of intrafami1ial spread of HBV infection was also found but 
could not be tested statistically due to small sample size. HLA data are 
pending on the Maiao subjects and it is hoped that their addition to the pedigrees 
will help to elucidate the contribution of genetic factors to the host response 




In 1975, en route from Australia to the United States, I visited the island 
of Tahiti and while there, learned of the Institut de Recherches Medicales Louis 
Malarde (IRMLM), a Pasteur Institute affiliate located in Papeete and run by 
the French Army. The IRMLM conducts research in clinical immunology, biochemi¬ 
stry and marine biology, with a special emphasis on the endemic diseases which 
imoose great burdens on the local population. 
In 1977 I contacted the IRMLM to investigate the possibilities for formal 
collaboration in scientific research. I was told that recent pilot studies 
suggested there existed a high prevalence of hepatitis B virus (HBV) infection 
on certain outlying islands of French Polynesia. The islands of Rapa and Rima- 
tara in particular (see map, figure 1),had villages where perhaps as many as 
90% of the native inhabitants showed serologic evidence of HBV infection. In 
contrast to this, villages on several other islands had infection rates of 
from 30 - 60%. 
In the course of discussing these IRMLM reports and reviewing the HBV litera¬ 
ture, several especially intriguing aspects emerged. First, although high infec¬ 
tion rates had already been documented in the South Pacific and other tropical 
areas, few of the other reports suggested rates as high as some of those from 
the IRMLM. Second, many of the studies done in the South Pacific had used rela¬ 
tively insensitive methods for HBV detection and had been limited to only random 
samplings of the populations studied. Thus, their accuracy and completeness could 
be brought into question. Also, none of the islands visited by the IRMLM had been 
included in these previous studies. Third, why did infection rates appear to vary 
so widely from one island to another? And finally, several hypotheses had been 
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put forth that genetic and other risk factors altered susceptibility to becoming 
chronically infected with HBV. Might these geographically, culturally and 
genetically isolated populations be a good model in which to study such factors? 
These were the major issues and questions addressed in this study. Dr. Robert 
McCollum, Chairman of the Department of Epidemiology and Public Health at Yale 
Medical School, agreed to sponsor this project. Dr. Jacques Laigret, Director, 
and Dr. Francis Parc, Chief of the Clinical Irmunology Section of the IRMLM in 
Tahiti, agreed to supervise and to provide technical assistance for the work in 
French Polynesia. 
Two trips to French Polynesia were ultimately involved. The first, from 
July to September, 1978, allowed us to partially address our initial questions. 
I returned to Yale with serum samples from the island of Maiao as well as some which 
had been previously collected by the IRMLM on Rapa and Mangareva. I also obtained 
a genealogy on Maiao. We were able to verify a large portion of the IRMLM 
pilot studies, and obtained a much more complete population sampling from 
the island of Maiao than had been available to most other researchers in the past. 
But two of our initial questions still remained unanswered i.e., were there in 
fact widely disparate infection rates among different islands and was there evi¬ 
dence for genetic susceptibility to becoming chronically infected with HBV? 
We needed follow-up date on these populations and therefore a return trip 
was planned. 
There were several goals for the return trip which ultimately took place 
from January to March 1980: 1) to attempt a more complete serum collection on 
the islands which had been visited originally by the IRMLM; 2) to return to Maiao 
to make a repeat collection which we hoped would provide essential infor¬ 
mation on the natural evolution of HBV infection in that population; 3) to 
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collect peripheral blood lymphocytes which could be used for more sophisticated 
tests of the genetic susceptibility hypothesis, and 4) to obtain genealogies from 
the populations on which they were lacking. 
As in 1978, the vicissitudes of nature and boat captains and the generally 
complex logistics of an operation such as this permitted partial fulfillment of 
these goals. In the end I succeeded in returning to Maiao and in my absence, 
an IRMLM team also went, for the first time, to the island of Hiva Oa. In 
both locations, we were able to collect blood serum samples and lymphocytes as 
well as to complete genealogies. This left us, then, with serum collections 




This was an audacious and complex undertaking from its inception. It was 
successful only because a large number of people gave extraordinarily generously 
of their time, energy, and expertise. 
Dr. Robert McCollum, Chairman of the Department of Epidemiology and Public 
Health at Yale University, was my thesis advisor and the one I first approached 
with the idea for this project. From the beginning of our collaboration he has 
given unselfishly of his time and extensive knowledge of hepatitis and of the 
formula for successfully conducting overseas research. He has done so to an 
extent exceeding even my most outrageous expectations. He arranged for a 
major portion of the funding, handled many complex administrative matters and 
insured crucial support of the staff within his Department, as well as else¬ 
where at Yale and in Tahiti. He read and then reread the drafts of this 
thesis. His faith in me was unremitting in the face of many obstacles, and he 
was the catalyst essential for the completion of this work. I will aways be 
grateful. 
Dr. Jacques Laigret, Director of the Institut de Recherches Medicales 
Louis Malardd' in Tahiti, graciously welcomed me into his laboratories, super¬ 
vised the arrangements for all of the field work and secured permission from 
the French Government for this project to proceed. His continued enthusiastic 
support for the day-to-day work and the alacrity with which he handled even 
the most delicate and complex problems was crucial to our success. 
Dr. Francis Parc, Chief of the Institut MaTard^’s Immunology Division, was 
my immediate supervisor in Tahiti. His expertise enabled us to sort out many 
of the methodologic problems that were encountered. He provided advice and sup¬ 
port in the planning of the field work in the form of laboratory space and equipment, 
supplies and transportation and the vital aid of many of his staff. 
Mr. Regis PIichart of the Institut Malarde worked very closely with me in the 
Institut Malarde laboratories as well as in the field in both 1978 and 1980. He 
obtained serum specimens, interviewed subjects, did a large portion of the work of 
lymphocyte isolation and freezing on Maiao and was soley responsible for the lym¬ 
phocyte work on Hiva 0a. He was extremely devoted to this work, and his assistance 
assured its success. 
Mr. Roy Capper of the Yale Department of Epidemiology and Public Health per¬ 
formed almost all of the serologic assays for evidence of hepatitis B virus infec¬ 
tion. His work was of such consistent high quality that the information he obtained 
formed the backbone upon which this entire study was constructed. He repeatedly 
saved the day by locating emergency relief supplies which admirably met even my 
most inexact specifications. 
Dr. Alan Williams, post-doctoral fellow in the Yale Department of Internal 
Medicine, and an expert in the field of hepatitis research, aided in this project 
from its beginning. He gave crucial guidance in the development of the study pro¬ 
tocol, and training in the HBV assay techniques. He personally tested our samples 
for the presence of the e-antigen and antibody. We have had many conversations 
nvaluable for the clarity which they imparted to my thinking about the behavior 
of hepatitis viruses and he has carefully read and critiqued the thesis itself. 
His help has been essential. 
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Dr. Kenneth Kidd of the Yale Department of Human Genetics gave important 
advice on research methods, supplied the prototype of the questionnaires which 
were used to obtain accurate pedigree data, and offered crucial insight into 
their interpretation. 
Ms. Allison Thurston-Palermo, formerly of the Yale-Tissue Typing Laboratory, 
trained me in HLA-typing techniques and helped to arrange for the shipment of 
HLA reagents to Tahiti. She also verified interpretations of HLA typings 
done in 1978. 
Dr. Robert Cone, Director of the Tissue Typing Laboratory, discussed the 
design of this project with me at the very beginning and very kindly permitted 
my training in his laboratory. 
Dr. Bernard Amos has arranged for the HLA typings of the populations of 
Maiao and Hiva 0a to be done in his laboratory at Duke University. 
Dr. John Dwyer of the Yale Department of Internal Medicine offered advice 
on research methodology and has permitted cold storage of lymphocyte samples in 
his laboratory. 
Mrs. Fran Nankee and Mrs. Marianne Mazan handled many administrative matters, 
arranged for purchase and shipping of research supplies and specimens all over 
the world - usually with very little advance notice. I am especially grateful 
for their persistent efforts to decipher many of my more cryptic communications. 
Drs. Michel Antoinetti and Bernard Philippe were the physicians-in-chief 
of the field trips to Maiao and Hiva 0a in 1980 and to Maiao in 1978 respectively. 
It was through their understanding and cooperation that the often cumbersome work 
of obtaining blood specimens and completing genealogy questionnaires was completed. 
In addition, they examined each of the subjects. 
Mr. Manu Gay, of the Institut Malarde, provided expert assistance in all 
phases of the work in 1978 and in the Tahiti-based work of 1980. He interviewed 
a large percentage of the Maiao inhabitants and played a major role in the col¬ 
lection of serum specimens. 
Mr. Eric Fuller, also of the Institut Malarde staff, aided in most aspects 
of the laboratory work in Tahiti and was a vital member of the field teams in 
both 1978 and 1980. His diligent and precise work helped to assure the accuracy 
of our results. 
Mr. John Alves, nurse at the Institut Malarde, assisted with the physical 
examinations on Maiao in 1980. 
Mr. Etienne Turia arranged for the cooperation of multiparous Tahitian women 
’ 
11 
from whom blood samples were obtained for use in HLA typing. In addition, he 
very kindly located housing for me during my 1978 stay in Tahiti. 
Dr. Ian Gust of the Fairfield Hospital, Fairfield, Australia, tested some 
of the 1978 Maiao serum collection for evidence of both HBV and hepatitis A virus 
infection. In addition, he discussed many aspects of this research both with me 
and with Dr. McCollum. 
Dr. Jay Hoofnagle of the National Institutes of Health tested many of our 
samples for the presence of anti-HBc. 
Dr. Lacy Overby of Abbott Laboratories supplied the Abbott Auscell testing 
materials that enabled us to field-test serum samples for the presence of HBsAg. 
Dr. Carl Cohen of the National Institutes of Health insured that we were 
provided with the NIH tissue typing reagents used in field tests at the Institut 
Malarde". 
Dr. Elliott Siegal of the Lister Hill National Center for Biomedical Communi¬ 
cations of the National Institutes of Health provided extensive listings of the 
National Library of Medicine's Hepatitis Knowledge base. These were a major source 
of references to the HBV literature. 
A large number of people discussed aspects of this research with me. They 
have given of their time and expertise in an enthusiastic manner and thereby assured 
that my work was both educational and enjoyable. These individuals include 
Drs. Francis Black, Fred f^antor, William Crede’, Wilbur Downs, Alfred Evans, 
Daniel Freeman, Fred Gorelick, Dorothy Horstmann, Denis Miller, Curtis Patton, 
Robert Shope, Byron Waksman and Steven Walter at Yale University, and Drs. 
Francis Louis, Gaston Pichon, Charles Tetaria and Paul Robert Thomas in Tahiti. 
I received financial support in 1978 form the Yale International Student 
Fellowship Program and personal as well as research support in 1980 from the 
National Fund for Medical Education which awarded me a SmithKline Foundation 
Medical Perspectives Fellowship (SK16/79B). 
Mrs. Amy Mangini typed this thesis. 
Finally, I wish to gratefully acknowledge the participation of the inhabi¬ 
tants of Maiao, Hiva 0a, Rapa and Mangareva who graciously permitted with open 




The goals of this research project were twofold: one, to study the epidemi¬ 
ology of hepatitis B virus (HBV) infection in native tropical island populations 
and two, to test the hypothesis that the development of the HBsAg-positive chronic 
carrier state as the host's response to infection with HBV is subject to genetic 
determinents. 
HBV epidemiology has been studied throughout the world and some of the highest 
infection rates have been found in persons living in tropical climates. With 
few exceptions, practical constraints necessitated that most of the studies con¬ 
ducted thus far were based on cross-sectional samples which may or may not have 
been representative of the total population at large. However, in spite of such 
uncertainties, the majority of authors reported very large proportions of appar¬ 
ently asymptomatic carriers of HBV virus in such tropical populations (18, 39-43, 
81, 121). Such a phenomenon has been reported only rarely (12, 114, 115) else¬ 
where. 
This project was initially conceived as an attempt to either confirm or 
refute these past observations in the more suitable model of an isolated popu¬ 
lation in which major sample biases could be eliminated by testing nearly all 
members of the community for evidence of HBV infection. In so doing, the more 
sensitive methods would be employed to detect past, acute or chronic forms of 
infection. 
Secondly, geographically and potentially genetically isolated populations 
constituted an excellent experimental model in which to address the question of 
genetic susceptibility to developing chronic HBV infection. When most people 
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are infected by HBV they have an acute and relatively short-lived infection which 
resolves as the host synthesizes antibodies to the infecting virus. However, a 
smaller number of people seem not to mount such an antibody response and remain 
persistently infected with HBV i.et, chronic carriers of HBsAg. If there is in¬ 
deed a genetic basis to the development of the chronic carrier state, one might 
see the clearest evidence of its operation by studying a population in which a 
large proportion of individuals are infected with HBV and which is isolated 
enough that the gene pool is relatively stable over at least several generations. 
Persons living on remote tropical islands who travel infrequently and who re¬ 
ceive few vistors seemed to be just such a population - assuming one could 
practically gain access to them. 
Past studies of island populations have used as their measure of a genetic 
influence on the development of the carrier state the frequency of clustering 
of chronic carriers within families (7,83). Conclusions based on such data may 
well reflect the operation of other than genetic influences. The next level 
of sophistication is to look for patterns of transmission and acquisition of HBV 
infection in detailed population pedigrees. This has been reported on a limited 
basis (11, 80, 101, 117, 138, 145), but only in isolated families not part of 
these tropical populations. However, the method of pedigree analysis, when 
used alone, is still of limited power compared to when it is used with more re¬ 
cently developed methods of genetic analysis such as HLA typing. 
HLA typing is based on a biologic assay of the gene products directly involved 
in human immune system regulation. Thus, we hoped to include in this study not 
only seroepidemiologic documentation of HBV infection in isolated tropical 
populations, but also a genetic analysis of the development of the chronic carrier 
state based on both pedigree analysis and HLA typing. 
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In the end, we were able to address all of our original questions, although 
all of the results cannot be presented and discussed in this thesis. The sero- 
epidemiology of HBV infection in native inhabitants of four islands in French 
Polynesia is reported here. In addition, longitudinal serologic data relating 
to the development of the chronic carrier state, as well as a genetic analysis 
based on pedigree data, are reported for one of these islands. The complex nature 
of the HLA analysis and the length of time required for its completion make it 
necessary to present those data in a separate report. 
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HEPATITIS B VIRUS STRUCTURE AND SEROLOGY 
Hepatitis B virus has a unique structure among viruses known to cause disease 
in humans. It has a 43 nm spherical shape (also known as the Dane particle) with 
a 27 nm inner core containing a unique combination of double-stranded circular DNA, 
and a specific DNA polymerase. There are three different major antigenic deter¬ 
minants: the surface antigen (HBsAg), the core antigen (HBcAg) and the e-antigen 
(HBeAg). HBsAg reactivity is found on the surface of three particles: the Dane 
particle and the 22 nm spherical and filamentous forms which result from excess 
hepatocyte protein coat synthesis in the infected host. HBcAg reactivity is found 
on the 27 nm inner core;and HBeAg reactivity also appears to be associated with 
the Dane particle core (89). HBsAg has a group-specific determinent "a"' and 
two mutually exclusive subtupe pairs, "d" or "y" and "w" or "r". HBsAg is 
therefore classified as subtype adw, adr, ayw or ayr (69). 
Each of the HBV antigens has a corresponding antibody which may be synthesized 
by the host in response to infection. 
SEROLOGIC RESPONSES TO HBV INFECTION 
Circulating HBsAg has been detected as early as six days after parenteral 
HBV exposure, but is usually first detectable starting from four to six weeks 
prior to onset of the clinical symptoms of acute infection (66) and persists for 
a period of from one to four months thereafter (see figure 2). However, studies 
of experimental inoculation have shown a very wide range of duration of HBsAg 
positivity ranging from one day to many years (10, 63). A detailed discussion 
of the development of the HBsAg-positive chronic carrier state will be found in 
the section on epidemiology. Figure 3 shows an example of the evolution of 
serologic markers of infection in a chronic carrier. 
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Although HBsAg appears to be intimately related to the infective, disease 
transmitting particle of HBV (105), it has been shown that blood (or other tissue) 
which does not contain measurable HBsAg can also produce HBV infection (35). This 
phenomenon may be due to the insensitivity of a particular assay, but may also 
result from having assayed the infective material at a time in the natural course 
of HBV infection when HBsAg production is declining in proportion to increasing 
synthesis of anti-HBs (precipitating antibody)i.e., sampling is done during a 
relative steady-state when the circulating amounts of antigen and antibody are 
balanced and bound in such a way that no net antigen or antibody is measurable. 
This is represented in figure 2 as occurring at about for to five months after 
infection. 
The core of the Dane particle has its own antigenic specificity, HBcAg. Al¬ 
though HBcAg positivity during clinical infection is relatively short-lived compared 
to that of anti-HBc (126), HBcAg appears earlier in the disease course during the 
interval of combined HBsAg and anti-HBs negativity (14, 55, 141) and thus may 
provide the only evidence of HBV infection in otherwise seronegative serum (62, 91). 
This could in part explain the cases of HBV transmission by transfusion of supposedly 
HBsAg negative blood (54) mentioned above. For these reasons, anti-HBc determination 
are assuming an increasingly prominent role in studies of HBV epidemiology. 
The functional significance of the HBeAg/anti-HBe system is discussed in 
the section on HBV epidemiology. It is currently considered important because 
of its potential value as a predictor of the infectivity of HBsAg-positive material 
as well as of the duration and resolution of infection. The time course of HBeAg 
and anti-HBe appearance is indicated in figure 2. Serum HBeAg is found only 
when HBsAg is present (14, 92, 118) and may be associated with unusually high 
' 
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titers (by RPHA) of HBsAg (93, 118). In a situation analagous to that suggested 
for HBsAg and anti-HBs, there may be a transient period of combined HBeAg/anti- 
HBe seronegativity when no net excess of either is present. This is depicted 
(figure 2 ) to occur starting at about three and a half months post infection. 
In a discussion of data collected from a large study of experimentally 
infected volunteer male prison inmates, Hoofnagle et al. summarized five patterns 
of serologic response after exposure to HBV (53). These are indicated in Table 2. 
Because this thesis is particularly concerned with the development of the chronic 
carrier state, an example of the serologic responses to HBV infection in a patient 
who went on to become a chronic carrier is shown in figure 3- 
Serologic assays 
Several different techniques, varying considerably in both sensitivity and 
specificity,are available and have been employed in the past as assays for each 
of the three major HBV antigen/antibody systems as well as for subtyping. These 
are summarized in table 1. Of note is that there are dramatic differences in 
sensitivity between the assays commonly employed today (the RIA and PHA or RPHA 
tests) for HBsAg and anti-HBs and those utilized in much of the early research 
on HBV epidemiology. 
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EPIDEMIOLOGY OF HBV INFECTION 
Worldwide Prevalence of HBV Infection* 
Studies of hepatitis B prevalence have been conducted in most parts of 
the world, representing a wide variety of communities and climates. 
Measurement of HBsAg has been the most often employed assay for evidence 
of "HBV infection". A committee of the World Health Organization has defined 
the HBsAg carrier (based on a survey of longitudinal studies) as "the presence 
[in the blood] of HBsAg for more than six months" (3). The number of human 
carriers was estimated to be 120 million in 1977 and HBsAg prevalence (but 
not carrier state) in "apparently healthy" adults varied from 0.1% in Europe, 
North America and Australia to 15% and more in some tropical countries. In 
countries where HBV infection was uncommon the highest prevalence of HBsAg 
was found in the 20-40 year old age group but, where common, the highest pre¬ 
valence was in 4-8 year old children (3). 
A 1978 review by Szmuness et al. (126) gave worldwide HBsAg prevalence 
figures of less than 0.5% in the U.S. and Western Europe, 1-2% in South America 
and Southern Europe, 3-5% in North Africa and the U.S.S.R. and 6-10% or higher 
in some parts of Africa and Southeast Asia. It also suggested a combined in¬ 
fection rate (persons with HBsAg plus those with anti-HBs and anti-HBc) of 
7-10% in the U.S. and 60-80% in Southeast Asia or Africa. 
It should be pointed out that the figures reported above are average 
values derived from surveys of large populations and that smaller, special popu¬ 
lation groups may have infection rates very different from those found in the popu¬ 
lation at large e.g., drug addicts or institutionalized patients. This probably re¬ 
flects a combination of factors including increased frequency of occurrence of certai 
* Many of the references included in this section were first listed in the Hepatitis 
Knowledge Base (July 1980 version), kindly supplied by the Lister Hill National Cen¬ 
ter for Biomedical Communications. 
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modes of HBV transmission or increased susceptibility of the population to infection 
due either to genetic or to environmental factors which alter the host immune re¬ 
sponse. 
Modes of transmission 
Most authors tend to discuss HBV transmission in terms of "parenteral" or 
"nonparenteral" routes. As discussed by Mosley in a recent commentary (85), the 
term parenteral has become synonymous with "percutaneous". Certain proposed 
modes of transmission such as fecal-oral, vertical, sexual, respiratory, and 
the catch-all, "close association", have been lumped together under the term 
"nonparenteral", which in turn has become synonymous with "nonpercutaneous". 
Defining parenteral "as applicable to anything ...taken into the body in a 
manner other than through the digestive canal", Mosley goes on to say that there 
are two good reasons to abandon this parenteral vs. nonparenteral distinction: 
1) several of the routes of infection classified as nonparenteral i.e., oral, 
sexual or respiratory, may in fact be parenteral and 2) the nonpercutaneous 
"nonparenteral" routes such as sexual contact and vertical transmission may 
well prove to be far more significant epidemiologically than the percutaneous 
"parenteral" routes. Therefore, especially since the epidemiologic significance 
of these nonpercutaneous routes is very different worldwide, it may be inappropriate 
to lump them together under a single label. 
A somewhat different conceptualization has been advocated by Szmuness et al. 
(126). They proposed that variations in the mode of HBV transmission are "mediated 
by a large variety of risk factors". Three major categories of risk factors provide 
a framework within which mechanisms of transmission may be classified: (A) Enhanced 
“robability of exposure, (B) Enhanced probability of HBsAg persistence and 
(C) Both enhanced exposure and persistence. The details of their schema will be 
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found in table 3 and may be helpful in understanding the following discussion. 
Mechanisms 
1) Direct parenteral (intravenous or percutaneous) inoculation 
There are many studies documenting intravenous HBV transmission e.g., in 
hemodialysis patients (79), and recipients of blood and blood products (11, 88), 
via contaminated needles in drug abusers (22) or by accidental needle stick in 
medical personnel (79). There is even the suggestion that HBV-containing material 
may penetrate bare feet in some areas, thereby transmitting infection (131). 
The human bite may also effect HBV transmission (47, 77, 87) as might that of 
certain arthropods. This latter mechanism is of potentially greater concern 
in tropical climates where arthropods are especially numerous. Arthropod 
transmission of HBV from mosquitoes, bedbugs and cockroaches has been proposed 
(73, 86, 90, 95, 103, 140, 143) but its real ecological significance is unclear. 
2) Contact transmission 
This is perhaps the most controversial form of HBV transmission and there are 
many conflicting studies in the literature. The major proposed routes are sexual, 
oral (via saliva or ingestion of HBsAg-positive material) or fecal-oral. 
Indirect evidence in favor of contact transmission comes from studies of 
HAV outbreaks in which patients who clinically and serologically appeared to have 
hepatitis A were found also to be HBV-positive (23, 36, 49, 142). Other findings 
which suggest the operation of contact transmission include the spread of HBV by 
the fecal-oral (64) or other "nonparenteral" routes (50, 120, 125) in institutions 
for the retarded, the finding of high proportions of HBV infection among persons 
iving in the same households as a known HBsAg carrier (100,113, 122), the occur¬ 
rence of an area-wide epidemic andean outbreak among children in the absence of 
. 
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evidence for percutaneous transmission (135), and the occurrence of outbreaks 
under circumstances where a percutaneous mechanism seemed unlikely to operate 
(31, 133). Oral-oral or fecal-oral (136) as well as respiratory transmission 
(5, 136) have also been postulated to occur in other circumstances. 
Early evidence against contact transmission of HBV came from studies in 
which oral or nasal administration of presumed HBV positive material failed to 
cause clinical hepatitis in volunteer subjects (46, 76). However, it is known 
that the gut contains HBsAg inactivating enzymes (38, 102). 
A study of hepatitis B occurrence in contacts of persons receiving HBV- 
contaminated yellow fever virus vaccine showed few secondary cases (28, 99) 
and a plasmapherisis-associated epidemic in prisoners likewise showed few 
clinical cases among the secondary contacts of persons receiving the contami¬ 
nated blood products (59, 108). One must be cautious in interpreting these 
latter studies because, although they may have accurately reported the inci¬ 
dence of clinical hepatitis, they relied on the appearance of clinical signs and 
did not include the occurrence of inapparent HBV infection. 
The studies of possible venereal transmission of HBV have yielded inconsis¬ 
tent results. For example, some venereal disease clinic patients who professed a 
wide range of sexual contacts had an increased frequency of infection (30, 58) 
as did presumably promiscuous homosexual men (27, 124), although homosexual women 
did not(124). One study of prostitutes showed they had no greater frequency 
of HBV infection than did chaste nuns (18), whereas a study comparing pros¬ 
titutes to age-matched female blood donors or nuns (29) and another study 
of prostitutes alone (96) did show higher than expected prevalence of HBV 
infection among the prostitutes. 
3) Vertical transmission from mother to infant 
Vertical transmission probably plays a significant role in HBV propagation, 

22 
especially in populations where very high carrier and infection rates exist. 
It is conceivable that infection occurs either in utero (via HBsAg positive 
amniotic fluid or transplacentally), at the time of birth (secondary to 
contact with antigen-positive vaginal secretions or maternal blood) or, 
in the perinatal period by several possible routes. 
Evidence in favor of in utero transmission includes the finding of HBsAg- 
positive amniotic fluid at 37 weeks gestation (71) or at the time of birth 
(by Caesarian section) (34), and the finding of antigen-positive cord blood 
(presumably with HBsAg having been synthesized by the fetus after transplacental 
infection) in both antigen-positive (20, 71, 94, 110) and negative (110) mothers. 
For example, in one study 70% of babies became HBsAg-positive after birth when 
their mothers had been infected during the third trimester whereas only 6% 
became positive when infection had occurred during the first or second trimester 
of pregnancy (110). Indeed, one mother who had been infected at six weeks gesta¬ 
tion and who had subsequently become antigen-negative, nevertheless delivered a 
baby whose cord blood contained HBsAg (110). Dane particles have been observed 
in cord blood known to be positive (by RIA) for HBsAg (20). 
Both anti-HBc (110) and anti-HBs (94) can cross the placenta and there is 
indirect evidence that anti-HBs can cross even more readily than HBsAg (94). 
That transmission can occur at the time of birth is suggested by the finding of 
HBsAg-containing vaginal secretions in the mother and HBsAg in the gastric aspirates 
from newborns sampled at the time of delivery(71). In addition, it is obvious that 
the fetus may come in contact with HBsAg positive maternal blood during delivery. 
Finally, breast milk has been shown to contain HBsAg (13, 71, 74) although 
its role in transmission of infection is uncertain (13, 25, 71). 
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Epidemiological surveys do not directlyeW.date.the mechanisms of transmission, 
but they have suggested a significant role for vertical transmission of HBV in¬ 
fection. 
As is discussed elsewhere, infection prevalence is often highest in the younger 
age groups and early acquisition has been interpreted as indirect evidence of the 
operation of vertical transmission since in many societies the infants spend a sig¬ 
nificant portion of their time in close maternal contact. In a family study on 
Santa Cruz Island in the South Pacific (83), Mazzur found a clustering of HBsAg 
and anti-HBs positive children only in families with an HBsAg positive mother 
(21%). This suggested to her that vertical transmission is at least one important 
mode of spread of infection. Other studies have also found that disproportionately 
high percentages of infants born to HBsAg carrier mothers develop antigenemia 
in the first one to two years of life (13, 14, 25, 71). 
The role of the e-antigen/antibody system in vertical transmission has been 
extensively studied in the orient. One study of 23 HBsAg-positive (by immune 
adherence hemagglutination) Japanese mothers found that 100% (10/10) of babies 
born to those mothers who were HBeAg positive developed HBsAg during the first year 
of life. In contrast, none of the babies born to anti-HBe positive mothers did 
developed HBsAg. Of the remaining six babies born to mothers both e and anti-e 
negative, two developed HBsAg and four did not (93). Another study of HBsAg-positive 
Chinese women (using RIA) found that 85% (17/20) of babies born to HBeAg-positive 
mothers developed HBsAg and also that 31% (13/42) of babies born to HBeAg-negative 
mothers developed HBsAg. Only one mother in this study had anti-HBe (14). 
Age and Sex Distribution 
The literature contains a large number of reports of age and sex distribution 
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of HBsAg. The initial and now classic work in this area is that of Blumberg (17). 
His conclusion was that HBsAg occurs more frequently in males less than 20 years 
old. There have been a multitude of other studies which have tended to confirm 
the trend for increased frequency of HBsAg in young males, although the sex dif¬ 
ference has not always been significant nor the age group the same. The mechanisms 
accounting for these observations are highly debated and may reflect the interplay 
of cultural (82), genetic (16), or other factors. For example, sex-specific 
behaviors and occupations or sex-linked immunogenetic factors (a detailed dis¬ 
cussion will be found in the next section) may play a role. This is true in 
some of the remote tropical populations which have been studied (6, 17, 26, 
39-43, 81, 82, 123, 141), as well as populations in temperate (18, 37, 107, 
119) and colder (8, 12, 114, 115) climates. Table 4 summarizes some repre¬ 
sentative data. Almost all of these studies have incorporated simultaneous 
anti-HBs measurement and it is generally found that anti-HBs prevalence in¬ 
creases gradually with age. 
Anti-HBc distribution has received more limited study but may more ac¬ 
curately reflect HBV infection rates than either HBsAg or anti-HBs prevalence 
(whether used singly or in combination). A recent study (141) of five different 
South Pacific populations showed marked heterogeneity in HBV infection rates as 
determined by retrospective assays for anti-HBc in sera from the late 1950s and 
early 1960s. There were generally no significant differences in the prevalence 
of HBV infection in males or females, but the age-specific prevalence varied 
tremendously between Melanesian, Micronesian and Polynesian populations and in 
particular between two Polynesian islands (Tahiti and American Samoa) and two 
islands within French Polynesia (Tahiti and Bora Bora) itself. These data are 
also summarized in Table 4. Another study in Greenland reported a fairly good 
» 
25 
correlation of anti-HBc with HBsAg positivity in two populations which showed 
a 1.5:1 male:female ratio but no significant age-specific differences in HBsAg 
frequency (114). A third study in tropical Africa showed a gradual increase 
of anti-HBc with subject age, but no differences in sex distribution were 
found (26). 
Age-specific prevalence studies suggest that HBeAg decreases while anti- 
HBe increases with age among HBsAg-positive subjects and that HBeAg prevalence 
is highly correlated with a high titer of HBsAg (84, 92, 114). Only the relatively 
insensitive immunodiffusion assay was available for these studies. A newly de¬ 
veloped comrnercially available RIA will no doubt soon allow for a much more thorough 
investigation of the role of the e/anti-e system in HBV infections. 
Chronic Carrier State 
In the strictest terms cited earlier, the chronic carrier state is defined 
by serologic evidence of HBsAg positivity on two measurements separated in time 
by at least six months. Some studies have measured incidence of HBV infection 
to most accurately establish HBsAg carrier rates, but for obvious practical 
reasons, there are relatively few population studies with such multiple samplings. 
Rather, single point prevalence studies are commonly done, especially in the less 
accessible populations. As will be discussed more fully below, incidence studies 
which have shown relatively high HBsAg carrier rates (in the 10-20% range) have 
invariably found nearly the same age-specific rates on repeat samplings. There¬ 
fore, the empiric assumption is made, and indeed this has become the accepted 
practice, that high HBsAg point prevalence rates also accurately reflect HBsAg 
carrier rates. 
When HBV infection leads to the development of the chronic carrier state, 
HBsAg usually rises to a high titer over a period of several weeks and then 
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remains elevated due to persistent virus replication (53). The time of onset 
of post-infection viremia can vary and to some extent has been a function of the 
detection method employed. Krugman et al. (66) point out that the minimum incu¬ 
bation period was thought to be 60 days in the late 1940s when appearance of 
jaundice was used as a marker of infection, 41 days in the 1950's with transaminase 
enzyme elevations as a marker, 29 days in the early 1970s using complement fixation 
to measure HBsAg and now 5-7 days using a radioimnunoassay to measure viremia. 
In the typical acute HBV infection, surface antigenemia rarely persists for 
more than four months (66). Persistence for longer than this usually indicates 
the development of the chronic carrier state, although there are reports of loss 
of HBsAg and subsequent appearance of anti-HBs after periods of from six months 
to many years (63, 104, 116, 120, 137, 146). This may reflect the operation 
of several factors including a natural decline in antigen to undectable levels 
with advancing age (120), a differential morbidity/mortality due to HBV infection 
Cl37) or genetic factors (see below). For example, one report of a group of 
persistent carriers infected early in life suggested that HBsAg clearance could 
occur after 20-30 years of positivity (126). Of course, population studies which 
do not follow the same individuals over time do not directly measure the duration 
of the carrier state. The epidemiologic grounds for inferring such information 
are discussed elsewhere. 
If anti-HBs is made at all in chronic HBsAg carriers, it is probably in such 
small quantities as to be entirely complexed with circulating antigen (53). In 
rare cases a heterotypic antibody response occurs i.e.,directed against a dif¬ 
ferent antigen subtype. This may be an antibody response to an earlier infection 
while virus of a different subtype has infected secondarily (or vice versa) and 
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has been observed in both nonhuman primates (128) and in man (68, 127). 
Early studies of anti-HBc (51, 62, 65) found that high titers (detected by 
complement fixation) were seen in acute HBV infections and then declined to un¬ 
detectable levels within about one year, whereas they remained elevated in chronic 
carriers. It was suggested that high anti-HBc titers indicated continuing virus 
replication and therefore were also indicative of infectivty. More recent work 
has shown, however, that anti-HBc (as measured by RIA) can persist at low levels 
after recovery from infection, even when anti-HBs is present; thus it was sug¬ 
gested that persistent anti-HBc could indicate immunity rather than infectivity 
(66). Along these lines, it has been shown that two classes of anti-HBc molecules 
exist and that IgM-anti-HBc may be a marker of ongoing virus replication and infec¬ 
tivity while IgG-anti-HBc may be present for many years in persons with completely 
resolved infection (91). 
Evidence is accumulating that the e-antigen/antibody system may be associated 
with factors which determine the infectivity of HBsAg-positive material as well 
as the duration or outcome ofinfection. The presence of HBeAg during acute hepa¬ 
titis may be predictive of development of the chronic carrier state in some sub¬ 
jects (9), but at least one study has found no correlation at all (129). There 
is one report from Polynesia that 38% (21/56) of HBsAg carriers also had HBeAg 
whereas 4% (2/56) had anti-HBe (40). 
The Genstic Hypothesis of Susceptibility to HBV Infection 
A tremendous amount of scientific controversy and fruitful research were 
generated by Blumberg in 1969 when he proposed that susceptibility to persistent 
infection with HBV is inherited as an autosomal recessive trait (16). His ori¬ 
ginal hypothesis was based on family studies of tropical populations living in 
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two separate island communities where he found a remarkably close fit between 
predicted and observed frequencies of HBsAg as measured by an immunodiffusion 
technique. 
His hypothesis, which predicted that only people homozygous for the suscep¬ 
tibility gene should become chronic carriers, was repeatedly tested in other 
populations. Early support came from a major study of some 700 Thai's living 
in a Bangkok housing development (39) as well as from a study of Caucasians living 
in Sardinia (21). 
The 1971 Thai study is worth going into in some detail. The population was 
picked to be a representative and random sample. Blood specimens were obtained 
at five and at nine month intervals and tested for HBsAg by both immunoelectroos- 
mophoresis (IEOP) and the more sensitive RIA>and for anti-HBs by IEOP and PHA. 
Only 1/679 (0.1%) of the subjects tested developed clinical hepatitis. Serum 
glutamic oxaloacetic transaminase levels were virtually identical for those 
persons positive or negative for anti-HBs and generally not elevated (81%), to 
only slightly higher (5%)^ but still normal in those positive for HBsAg. Of the 
nearly 700 original subjects, 523 were followed with paired serum determinations and 
of these, 37/39 (95%) who had been HBsAg-positive originally remained positive over 
the nine month period. Age-adjusted HBsAg prevalence rates were 10% males, 7% female 
and 8% combined^nd were significantly higher in males than in females of ages 10-29 
years. Anti-HBs prevalence was higher in males up to age 60 years with overall 
in 
prevalences of 52%Amales, 42%Afemales and 46% combined. When HBsAg and anti-HBs 
positives were taken together as an overall measure of HBV prevalence (anti-HBc 
was not measured), 21% of children 1-4 years old were infected and there was a 
steady rise in infection rate to a level of 68% in the greater than 40 year old 
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age group. Combined incidence of HBV infection (those subjects who acquired either 
HBsAg or anti-HBs during the nine month study period^ and who had been negative for 
both at the onset) was 13% and was also greatest in the 1-4 year old age group. 
Finally, by adding to those who had developed new HBsAg or anti-HBs, the number 
of individuals who showed serologic evidence of reinfection, as defined by at least 
a four-fold increase over baseline anti-HBs titer (such anemnestic responses have 
been documented elsewhere (24, 126), the authors calculated that as much 
as 19/ of the entire population could have been infected during the nine month 
study period. 
From these data they concluded that (1) since two-thirds of those infected 
showed evidence of re-infection during the study period, it was probable that 
nearly everyone in the community would be infected one or more times in his life¬ 
time and (2) since some people in every age group lost serologic evidence of in¬ 
fection, overall HBV prevalence could never reach 100%. It plateaued at 67% in 
this population. 
Next, they found no significant differences in infection rates as a function 
of likely risk factors, i.e., a history of hospitalizations, medical infections, 
dental work, tatooing, blood donations, blood transfusions or jaundice. Since 
they had concluded that a large majority of HBsAg-positive subjects were probably 
long-term carriers, they were surprised at the lack of increased relative risk in 
these carriers, although they did point out that poor sanitation, crowding and 
"frequent intimate contact" were the rule, and that potential arthropod vectors 
were widely prevalent. 
All in all, these findings suggested to the authors that genetic susceptibility 
0 HBV infection might play a role in the development of the chronic carrier state. 
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Furthermore, there was a significantly higher prevalence of HBsAg among children 
in families in which the mother was HBsAg-positive. They suggested this might 
be due to more prolonged and intimate contact between mothers and children (at 
least at very young ages) which afforded greater opportunity for the child to 
become infected. In the end they decided their findings were most consistent 
with the hypothesis that genetic susceptibility (although they did not specify 
Blumberg's autosomal recessive mode) to HBV infection operates to favor the 
development of the HBsAg-positive chronic carrier state. 
A 1973 study of HBV prevalence in Senegal (121) also considered the genetic 
hypothesis in two separate groups of children between five months and 14 years 
of age and in servicemen, although only the data collected on children are dis¬ 
cussed. Among 1430 children, 16% of males and 11% of females (or 13% overall) were 
HBsAg-positive by agar gel immunodiffusion. Some 804 children were retested 
afcrsix months, including 105 of the original 186 who were HBsAg-positive 
, % 0%) 
and 99/105 (94%) remained HBsAg-positive while 18rtadditional children had 
acquired HBsAg. In contrast to the hypothesis proposed in the Thailand 
study, these authors , suggested that sanitary, socioeconomic, other environmental 
factors and perhaps vertical transmission played the major roles in causing the 
high carrier rates. They could not account for the observed sex differences 
(HBsAg 50% higher in males), although the pattern of higher HBsAg carrier rates 
among males noted in many population studies (8, 17, 37, 123) appeared to be 
environmentally and culturally induced on one South Pacific island (82). 
Bcinffer et al. (7) studied ethnically distinct groups of Indians, Creoles 
and Indonesians living in the capital city of the Republic of Surinam in 1974. 
Although HBsAg prevalence was 19% in the Indonesians vs. 3-8% in the other groups, 
the authors postulated that family clustering of carriers (which was "suggested" 

31 
by their data) may have been due to a greater exposure risk rather than to a 
genetic susceptibility. Since it appeared that the Indonesians were among the 
last groups to move from their native homeland to the city, perhaps they brought 
with them a greater HBsAg prevalence which was in the process of decreasing to 
the levels of the surrounding populations. In other words, their particular 
household environment/life-style, although beginning to conform to new surroundings, 
still placed them at increased risk for becoming chronic carriers. 
Early evidence against this hypothesis was the finding in a Sardinian family 
that only 2/7 children of an HBsAg-positive mother and father (presumably both 
homozygotes) were HBsAg positive by immunodiffusion assay (101). However, some 
doubt was raised as to whether all of the children had in fact been exposed to 
HBV. In 1974 Vyas studied a Chinese family (138). The parents both remained 
HBsAg-positive (by RIA) over a six month period whereas two children were both 
antigen and antibody negative and the third child anti-HBs positive during the 
same period. Lederberg (70) pointed out at the same time that family clustering 
of HBsAg carriers could probably be explained on the basis of spread through 
prolonged close personal contact without invoking a genetic basis. Key family 
studies published in 1976 (80, 117, 145) and 1977 (83) also had results incom¬ 
patible with the autosomal recessive hypothesis. 
In 1975, Szmuness et al. published a paper which went far towards clari¬ 
fying the environmental vs. genetic influences debate (119). They studied 751 
New York City families of blood donors and found that in families with an index- 
donor HBsAg-positive, overall prevalence of HBV infection was ten times as high 
as in control families of the same ethnic background. Similarly, in families 
with an anti-HBs-positive index donor, prevalence was two to three times as high 
as in controls. Genetic segregation analysis suggested an excellent fit with 
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the autosomal recessive hypothesis and in two of three families with both parents 
HBsAg-positive, all progeny were also antigen positive. 
Their comments on the significance of their own and others' (11, 80, 101, 
117, 138, 145) pedigree analyses, even though published before some of these 
other studies, bear repeating here. First, failure to detect antigen in progeny 
of putatively homozygous parents may reflect the inability of the testing method 
employed to detect low levels of antigen, the fact that HBsAg carriage is not al¬ 
ways life long, or the possibility that susceptible progeny have not yet been in¬ 
fected (120). Even if the homozygous recessive hypothesis is incorrect, they state, 
the individual's response to HBV infection may be mediated by "some unidentified 
polygenic inheritance". The HLA system is certainly a good candidate to fill this 
role. 
The Histocompatibility System 
Chronic carriers only rarely show overt clinical signs of hepatitis (4, 10, 53) 
and they often show no or only mild elevations of transaminase enzyme levels (60, 61). 
It is widely believed that these observations reflect the operation of a host immune 
system tolerant to HBsAg (109, 138) secondary to abnormalities of white blood cell 
function. Although there is at least one report of neutrophil dysfunction in chronic 
carriers of HBsAg (134), most discussion by far has centered around alterations in 
lymphocyte-macrophage handling of HBV as leading to the development of persistent 
antigenemia. The immunologic function of these cells is thought to be largely under 
the control of the polygenic HLA system. 
The HLA system is the major histocompatibility complex in man and is believed 
to control, or at least to be in close genetic linkage with the genes that control, 
immune system function. HLA genes are multiallelic and code for different proteins 
found on the surface of all nucleated cells and also platelets (78). Interactions 
between immune system cells and host or foreign antigens (for example, HBsAg) are 
. 
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thought to be in large part keyed to these cell surface HLA antigens. 
The exact mechanisms which are postulated to lead to increased disease sus¬ 
ceptibility or the development of the chronic HBsAg carrier state, are beyond 
the scope of this thesis. However, HLA associations in patients with hepatitis B 
infection have been studied and are listed here for HLA loci A and B. Among persons 
who are HBsAg positive chronic carriers there are reports of an increased frequency 
of HLA loci All (111), A3/B19 (132), Bwl7/Bw27 (44), Bwl5 and B8(56). However, one 
study of chronic carriers found a decreased frequency of A2/Bwl5 (19). In chronic 
carrier hemodialysis patients, positive associations have been reported between 
loci All (.111), B8 (98) and Bwl5/Bwl7/Bw35 (48). One study found no associations (57). 
Many population studies have confirmed the observation first made by Blumberg 
in 1969 (17) that HBsAg occurs more frequently among males. In a more recent 
study of HBsAg-positive hemodialysis patients in which Blumberg participated (75), 
the suggestion was made that y chromosome-linked genes, perhaps in concert with 
HLA histocompatibility antigens, influence the male host response to HBV infection. 
Rapid progress is being made in HLA typing technology so that significantly 
more specific reagents are available now than were used in some of the studies 
quoted here. At present, there are still no universally agreed upon associations 




Blood samples were collected from Maiao and Hiva Oa during two separate trips 
to French Polynesia, in July of 1978 and January of 1980. The purpose each time 
was to obtain and preserve, from each subject,blood serum for HBV serology, peri¬ 
pheral blood lymphocytes (for HLA typing), to perform physical examinations and 
to compile a genealogy of the entire population. Blood samples from Rapa and 
Mangareva had been collected previously by IRMLM personnel. In both years, the 
research team was comprised of a physician, nurse, and two technicians from the 
IRMLM. I was present for the field work on Maiao in 1978 and 1980. The Hiva 0a 
specimens were collected by the IRMLM team. Transportation of personnel and 
equipment was accomplished using various combinations of boats and airplanes 
as were necessary to assure adequate collection times and the preservation of 
the specimens. In total, 792 blood specimens were obtained. 
Each island to be visited was contacted by radio in advance of arrival and 
the nature of the visit explained. This research was conducted within the con¬ 
text of the annual or biannual medical missions to outlying islands which are 
conducted by the staff of the IRMLM and the Public Health Department in Tahiti. 
Thus venipuncture and physical examinations would have been performed as a mat¬ 
ter of routine and were readily accepted by the populations. Yale University 
Human Investigation Corranittee approval of this design was obtained beforehand. 
Data were collected over 5-10 day periods which varied from island to island. 
In 1978, trips were made to the islands of Rapa, Mangareva and Maiao. At 
that time blood samples were collected on all three islands and a geneaology com¬ 
pleted on Maiao. Lymphocytes for HLA typing were not collected. 
In 1980, a return trip to Maiao was made and a repeat serum collection and 
ymphocytes obtained. This repeat serum collection was intended to provide 
information on acquisition of HBV infection since the 1978 baseline collection. 
■ 
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Similarly, blood serum, lymphocytes and a genealogy were obtained in the village 
of Atuona on the island of Hiva Oa. 
Serum Collection 
Blood samples were collected under sterile conditions by standard venipuncture 
techniques. Approximately 10 - 15 ml of blood was placed into dry tubes and allowed 
to clot for serum separation. Separated serum was stored in labelled tubes at 
+4°C while in the field locations (usually for several days) and then frozen at 
-20°C once returned to the IRMLM. They were eventually shipped on dry ice to 
Yale University and kept at -20°C thereafter. 
Genealoqj es 
Genealogy data were acquired by multiple interviews with each family in a 
given village. This was accomplished with the help of several IRMLM technicians 
fluent in the local Polynesian dialects and we employed a specially designed 
questionnaire (see example in figure 4) supplied by Dr. Kenneth Kidd of the 
Department of Human Genetics at Yale. Data were subsequently transcribed for 
pedigree analysis. 
HBV Serology 
Serum samples were analyzed at Yale University. All sera were first tested 
for the presence of anti-HBs by reversed passive hemagglutination (RPHA, commer¬ 
cially available from Abbott Laboratories). HBsAg-positive samples were further 
tested for HBeAg and anti-HBe by agar gel immunodiffusion (69). Surface antigen/ 
antibody negative samples were tested for anti-HBc by radioimmunoassay (CORAB, 




All of the subjects were native-born inhabitants of the islands under study. 
They are principally a Polynesian population but they have been intermittently 
visited by increasing numbers of Eurasians since the 18th century and there has 
been an unknown amount of interbreeding. 
Geographical Description 
French Polynesia is located in an area more than 6000 km from the nearest 
continent. It is composed of some 120 islands loosely grouped into five archi¬ 
pelagos located between 8° - 28° south latitude and 134° - 155° west longitude. 
Alaska is 7500 km and Hawaii 4400 km to the north, Antartica 5500 km to the south, 
and Peru 7800 km to the east. Micronesia, Melanesia, Indonesia and finally Australia 
(5300 km) lie to the West. A map of French Polynesia is shown in Figure 1. It is 
7700 km and a ten hour jet ride from Los Angeles to Tahiti. 
The islands are composed of two principle types, high volcanic and low coral 
atolls. Atolls are formed by the deposition of calcium carbonate coral skeletons 
onto a substrate of submerged volcanic rock. They are arbitrarily defined as being 
less than seven meters above sea level. Many islands therefore have both volcanic 
and coral elements. 
The Society archipelago is a group of fourteen mostly volcanic islands, the 
windward islands being Tahiti, Maiao, Moorea, Maheita and Tetiaroa, and the leeward 
islands Huahine, Raiatea, Tahaa, Bora Bora, Maupiti, Tupai, Mopelia, Scilly and 
Bellinghausen. 
The Tuamotu archipelago is composed of 76 atolls, of which Rangiroa is the 
■argest and best known. 
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The Gambier archipelago is really the southwesterly prolongation of the 
Tuamotu's and is made up of a large atoll named Temoe surrounded by eleven main 
islands including Mangareva and Aukena. 
The Austral archipelago is composed of seven islands of which the five 
principle volcanic islands are Rimatara, Rurutu, Tubuai, Raevavae, and Rapa. 
Finally, the northernmost Marquesas archipelago is comprised of ten vol¬ 
canic islands, including a northern group of which the main island is iJuka Hiva 
and a more southern group with Hiva Oa the main island (106). 
As can be deduced from study of the attached map of French Polynesia, access 
to many islands is limited by the great distances involved. There are few air¬ 
ports and none of the islands in this study had hotels. Only Mangareva had any 
permanent foreign residents. These islands only rarely receive outside visitors and 
the islanders themselves travel even more infrequently. 
Maiao, one of the society islands group, is a small mountainous island lo¬ 
cated 185 km from Tahiti: It measures about 5x5 km, with its tallest point 
150 m, and has a central mountain ridge bordered by swampy flatlands and an 
outer ring of coral sand. It is entirely surrounded by a barrier reef except 
for two small passes. There is a single village of some 200-225 inhabitants 
living in about 35 houses. 
Hiva 0a is a mountainous island in the Marquesas group, some 1200 km north¬ 
east of Tahiti. It is famous as the setting for Melville's T.ypee and as the 
burial site of Paul Gauguin. Atuona village is located in an isolated valley called 
Pua mau. It consists of about 170 inhabitants living in a cluster of 35 houses. 
Mangareva is a high island 1450 km southeast of Tahiti. It is a large island 
surrounded by a number of smaller islands which are actually raised portions of 




Rapa is also a high island and perhaps the most isolated of all the inhabi¬ 
ted islands of French Polynesia, located 1100km southeast of Tahiti. There are 
two villages, Ahurei and Area, located close to one another with a population 




The work was carried out in two stages, sample collection and then laboratory 
testing. The sample collection in French Polynesia was done with the cooperation 
of the Institut de Recherches Medicales Louis Malarde" (IRMLM) in Papeete, Tahiti. 
Subsequent work was done at Yale University. 
The IRMLM is the center of scientific research in French Polynesia and indeed 
one of the preeminent centers in all of the South Pacific. Its main laboratories 
and offices are located in the city of Papeete on the island of Tahiti, but it 
also has an insectorium, marine stations and other facilities located elsewhere 
on Tahiti and on other islands. The IRMLM holds outpatient clinics both at the 
Institut itself and in liason with the Public Health Service, on almost all of 
the inhabited islands of French Polynesia. 
The staff is composed of the Director, the Chiefs of the three main divisions 
(Clinical Immunology, Marine Biochemistry and Arbovirus Research), a physician in 
charge of clinical activities and^a large number of laboratory technicians, 
nurses and other personnel. 
The HBV serology and all data analyses were carried out in the Department 




In 1978, blood samples from 151 individuals living on the islands of Maiao, 
Rapa and Mangareva were tested for HBsAg, anti-HBs or anti-HBc. In 1980, 156 
individuals on Maiao were tested in addition to 120 persons living on Hiva 0a. 
The relative proportion of the total population represented by the individuals 
tested is shown in Table 5. In the following discussion, the 1978 Maiao samples 
provide baseline data and thus the 1980 collection is used only for comparison 
purposes in deriving measures of HBsAg carrier state and incidence of new HBV 
infection. Furthermore, because there are inadequate census data to indicate how 
the study subjects are representative of an entire village or island population, 
no effort is made to combine and compare data between the islands where less than 
40% of the population was tested; to do so would be an inappropriate pooling of 
potentially biased samples. 
Anti-HBc was measured only in those subjects without either HBsAg or anti-HBs 
in order to obtain the most complete possible estimates of the extent of HBV in¬ 
fection. Therefore, since anti-HBc was not measured in the entire population, 
no overall age and sex distribution data for this specific measurement can be 
reported. 
Physical examinations performed on the entire populations of both Maiao (1978 
and 1980) and Hiva 0a (1980) yielded no clinical evidence of acute or chronic 
hepatitis such as jaundice, hepatomegaly, ascites* etc. 
Distribution of HBV Infection 
The evidence of past or current infection with HBV among the subjects tested 
on each island is shown in Tables 6-9. On both Hiva 0a and Maiao, greater than 
70% of the repsective village populations were sampled. 
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On Hiva Oa (Table 6), 58% of males, 73% of females or 70% of all subjects 
were infected. Similarly, HBsAg was found in more females than males (16% vs. 
24%) although the sample size was small enough that no clear-cut age distribution 
could be seen.Anti-HBs was about equally prevalent in both sexes. 
The 1978 Maiao results (Table 7) show quite a different distribution of 
infection. Overall, 95% of males, 83% of females or 88% of all subjects were 
infected. In both sexes the infection rates were lower in the 1 - 9 year olds 
and rose to higher levels thereafter. Although HBsAg rates fluctuated between 
age deciles ,in both sexes they rose to a peak in the 30 - 39 year olds and de¬ 
clined rapidly thereafter so that none of the seven persons over 60 years of age 
had HBsAg. Overall infection rates ranged from 86 - 100% in all but the 1 - 9 
year olds, and it can be seen that a low HBsAg prevalence was always counter¬ 
balanced by a proportionally higher combined anti-HBs plus anti-HBc prevalence 
e.g., the 60 year olds with no HBsAg had the highest proportion of antibodies 
(anti-HBs plus anti-HBc). 
The test results from Rapa are found in Table 8. Forty-four percent of the 
inhabitants were tested and it is impossible to know how these individuals rep¬ 
resent the general population. The overall infection rate in this population 
sample was 96%. Even if none of the remaining 66% of the islanders were in¬ 
fected, the HBsAg prevalence would be 25% at a minimum and the total infection 
rate would still be greater than 42%. Although theoretically possible, it seems 
intuitively unlikely that our sample was biased to this extent and therefore it is 
probable that a major proportion of the Rapa inhabitantsvere infected by HBV. 
Similarly, serum from 40% of Mangareva inhabitants was tested for HBsAg 
and anti-HBs, although anti-HBc determinations were not made. Results are 
presented in Table 9. This sample was most heavily distributed in the 10-19 
. 
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and 40 - 49 year old age groups and was probably biased because of this. 
Persistence of Infection 
A second serum collection was made on the island of Maiao in 1980, nineteen 
months after the one made in 1978. Although 151 sera were tested in 1978 (Table 7) 
and 156 in 1980 (Table 10), only 100 individuals were followed and tested at both 
times. Only 100 persons received follow-up testing because some refused veni¬ 
puncture on one occasion, were off of the island at one time or the other, or 
had died between 1978 and 1980. 
Table 11 shows the test results of the 100 persons from whom there were paired 
samples. As was the case with the entire population present in either 1978 or 
1980, the infection prevalence was lowest in the 1 - 9 year olds, but nonetheless 
high at 78%,and remained at a relatively constant high level thereafter. 
Table 12 is a summary of the net serologic changes occurring in the group of 
100 subjects tested in 1978 and 1980. One 24-year-old male converted from HBsAg 
to anti-HBs and one 33-year-old female from HBsAg to anti-HBc. Eight persons 
converted from anti-HBc to anti-HBs and one converted to negative. Of the eight 
persons negative in 1978 and tested again in 1980, seven converted to anti-HBs 
(four females and one male less than nine years, one male of eleven years, one of 
37 years and one female 54 years of age) and one remained negative (an eight-year 
old female). This latter group comprised the portion of the population susceptible 
to becoming infected with HBV and from these results one can calculate the incidence 
of new HBV infection during the nineteen-month study interval; 
7 (number of susceptibles acquiring infection) _ ^ ^ 
100 (total population) - 92 (number already infected) 
This figure may be converted to an equivalent 55% yearly incidence of HBV 
infection among those susceptible. 

43 
Distribution of HBeAg and Anti-HBe 
Table 13 shows the frequency of occurrence of HBeAg and of anti-HBe among HBsAg 
positive subjects, for each of the islands. 
Composition of Subject Pool 
Greater than 70% of the inhabitants of the islands of Maiao and Hiva 0a 
were tested for evidence of HBV infection. An additional 40-41% of inhabitants 
of two other islands, Rapa and Mangareva, were also tested (Table 5). 
Since precise census data were unavailable for any of the islands, it 
cannot be known for certain whether the subjects tested represent random samples 
of the respective populations. Because a relatively small proportion of the Rapa 
and Mangareva inhabitants were tested, the magnitude of cross-sectional sampling 
errors was uncertain and these individuals and islands were excluded from compari- 
tive statistical analyses. However, they will be dicussed in qualitative terms. 
On the other hand, a much greater proportion of the Maiao and Hiva 0a inhabitants 
were tested. Observations made at the time of sample collection on these islands 
did permit the consideration of possible sampling errors. 
In particular, it was likely that the majority of the approximately 30% 
of untested individuals on Maiao or Hiva 0a were in the 1-9 year old age group. 
No newborn infants and very few children under five years of age were tested, 
largely due to parental anxiety over the risks of venipuncture. What was felt to 
be a conservative estimate of the number of young children involved was made by 
the medical team and suggested to be approximately 50% of the untested subjects 
of each island. This estimate was derived from comparing the list of persons 
ested with that of those who had received physical examinations. This latter 
group comprised essentially the entire village populations. 
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Looking at the specific numbers involved, on Hiva Oa (Table 6) 13 (11%) of 
the 120 subjects tested were 1 - 9 years old, so that of the 50 untested 
subjects, 25 were estimated to also fall into this age group. By adding in 
this number, it could be calculated that 38 (22%) of the total population of 
170 persons were 1 - 9 years old and that those 25 not tested in this age group 
represented 15% of the total population. The remaining 25 untested persons were 
randomly distributed among age groups as far as was known and prepresented 
another 15% of the population. 
On Maiao (Table 7), 37 (24%) of the 152 subjects tested were 1 - 9 years 
old, so that of the 54 untested subjects, 27 were estimated to also fall into 
this age group. By adding this number, it could be calculated that 64 (31%) 
of the total population of 206 persons were 1 - 9 years old and that those 
27 not tested in this age group represented 13% of the total population. As 
on Hiva 0a, the remaining 27 were believed to have been randomly distributed 
among all other age groups and represented another 13% of the population. 
Pedigree Analysis 
Two family pedigrees were constructed for the population of Maiao (figures 
5 - 8). They include 116 (56%) of the 206 inhabitants and are annotated with 
the results of HBV serologic testing, including those from 65 of the 100 subjects 
who were tested on two occasions. Cases of unremembered or questionable parentage 
were eliminated from the pedigrees. 
When these pedigrees were viewed in conjunction with the composite population 
data from Maiao (Tables 7 and 10 - 11), it was seen that from 96 - 100% of the 
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populations became infected with HBV by the age of ten years. Indeed, of the 
18 persons not infected in 1978, 13 were less than 10 years, two 10-19 years, 
one 30 - 39 years, one 40 - 49 years and one 50 - 59 years of age. 
It will be recalled that the hypotheses prospectively considered included 
the possibility that the development of the HBsAg-positive chronic carrier state 
was genetically determined, that children of HBsAg-positive mothers were more 
likely to become chronic carriers themselves and that children of HBsAg-positive 
mothers were more likely to become infected at an early age than those of mothers 
who were not carriers of HBsAg. Evidence for and against these hypotheses is 
presented below. 
Distribution of Infection Within Families 
Looking at all families in both pedigrees, there were two HBsAg-positive 
mothers. Of their nine tested offspring (ranging in age from 4-11 years), 
four were HBsAg-positive, four anti-HBs positive and one negative by 1980 
(family A in figures 5 and 6 and family C in figures 7 and 8). The mother in 
family A had HBeAg and all four of her progeny had both HBsAg and HBeAg. 
The mother in family C was e/anti-e negative and all of her children had either 
anti-HBs (four) or were negative (one). The father of family A had anti-HBs in 
1978 and the father of family C was negative in 1978 but had anti-HBs by 1980. 
There are two families with HBsAg-positive fathers, B and C in figures 
5 and 6. Of the seven children tested (ranging in age from 4 to 11 years), 
all had developed anti-HBs by 1980 and none had HBsAg. The mothers in both of 
these families had anti-HBs. 
By using the method of chi-square analysis with 2x2 contingency tables, 
it was determined that 1)1-9 year old progeny of HBs-Ag positive mothers were 
more likely to have HBsAg (X^ - 4.802, n = 30, df = 1, p < .05) than were the same 
aged progeny of other mothers; 2) when progeny of all age groups were taken to- 
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gether, offspring of HBsAg -positive mothers were still more likely to have 
HBsAg (X2 = 4.401, n = 46, df = 1, p ^ .05), but that 3) infection per se was 
not more likely to occur in 1 - 9 year old progeny of HBsAg-positive mothers 
(X2 = .030, n = 31, df = 1, p = ns). The possibility that 1 - 9 year old 
offspring of an HBsAg-positive father were more likely to acquire HBsAg was 
also tested and could be rejected (X2 = 1.974, n = 29, df = 1, p = ns). 
Finally, the hypothesis that infection occurred more often in any nuclear 
2 
family in which any member had HBsAg was rejected (X = 0.065, n = 87, df = 1, 
p = ns). For the purpose of calculating these probabilities, the assumption 
was made ( 53) that those subjects who had anti-HBs in 1978 but were not tested 
in 1980, in fact still had anti-HBs in 1980. However, no results were inferred 
when HBsAg data were lacking. 
Genetic Mechanisms 
Autosomal dominant, x-linked recessive, x-linked dominant and y-linked in¬ 
heritance of susceptibility to becoming an HBsAg-positive chronic carrier did 
not appear to operate in this population. 
For an aitosomal dominant mechanism to be in operation, no infected progeny 
of a mating between two non-carrier parents should become chronic carriers (i.e., 
homozygous recessive parents could not produce either heterozygous or homozygous 
dominant offspring). However, figures 7 and 8 show families A and B to violate 
this rule since non-carrier parents (161, 124 and 34, 176) had carrier progeny 
(174, 185 and 36, respectively). 
An x-linked dominant mechanism would require that a carrier father have only 
carrier daughters. Figures 5 and 6 show this not to be the case in families B 
and C where carrier fathers (55 and 179) had non-carrier daughters (52, 72, 73, 
74 and 39, 40 respectively). 
In an x-linked recessive model, a carrier mother could have only carrier sons. 
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Family C in figures 7 and 8 shows a carrier mother (114) with non-carrier sons 
(107, 110) and thus argues against this mechanism. 
Y-linked inheritance would require that a carrier father have only carrier 
sons. There are numerous instances where this was shown not to be the case. 
For example, family C in figures 7 and 8 shows a carrier male (179) who was at 
the same time the son of a non-carrier father and the father of a non-carrier son. 
These pedigrees were consistent with the operation of an autosomal recessive 
mode of inheritance of susceptibility to developing the chronic carrier state. 
One could postulate either homozygous recessive x heterozygote, heterozygote 
x heterozygote, or homozygous recessive x homozygous dominant matings in all cases 
where chronic carrier progeny resulted and thereby account for all of the pheno¬ 
types observed in those families. For example, families B and C in figures 7 and 8 
could have resulted from homozygous recessive (55 and 179) x heterozygote or homo¬ 
zygous dominant (54 and 42) matings giving all non-carrier children. A hetero¬ 
zygote (161 and 134) x heterozygote (124 and 176) mating in families A and B 
in figures 7 and 8 could explain the observation of both carrier (174, 185 and 




As was discussed earlier, an ideal study of HBV epidemiology and the 
natural course of infection should include testing of all individuals in a given 
population. Thus, it was planned that this study inlcude the greatest posssible 
proportion of the individuals living on each island. The practical realities 
of a study such as this have made it impossible to fully realize such a goal 
i.e., parents were unwilling to have their youngest children tested, some people 
were away during our brief, limited study visits, some subjects refused to cooperate, 
and so forth. 
In addition, retrospective testing of previously acquired serum samples, 
such as those from Rapa and Mangareva, is more likely to yield biased results 
because of biased collection or sample depletion and alteration secondary to 
storage and handling problems. 
All things considered, the prospectively planned surveys on Maiao and Hiva 
Oa came reasonably close to complete samplings i.e., 74% and 71% respectively. 
It was estmiated that 75% of untested subjects on Maiao and Hiva Oa were less 
than 10 years old. On both islands this was the age group having the lowest 
infection rate and although it is tempting to assume that those subjects who 
w_ere tested in fact represented an unbiased sample of their age group, there is 
no way to be certain. However, if this assumption were correct, then the finding 
of lower overall infection rates in young children would mean that they comprised 
the largest pool of uninfected, susceptible individuals, as would be expected for 
any endemic infection where increasing levels of population immunity would occur 
with increasing age. If the youngest children had a similar risk of exposure to 
HBV as other aged persons, one would have to postulate e.g., they had immunologic 
protection against acquiring infection which older persons did not, perhaps per¬ 
sisting maternally-derived anti-HBs (94). On the other hand, if they were at a 
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lesser risk of exposure to HBV then that fact alone could account for the decreased 
prevalence of infection among them. It is interesting that the earliest studies done 
in the South Pacific found the greatest HBsAg prevalence in young children, 
(6, 15, 17) while more recent studies using more sensitive assays have had 
results similar to ours (40-43, 141). 
One can certainly imagine that the children who were still physically very 
dependent on their mothers were at a decreased risk for exposure to HBV-contami- 
nated materials because they were not out playing, had fewer intimate contacts 
with the population at large, and so forth. If they were exclusively breast fed, 
and their mothers did not have HBsAg in their milk, then they may have had even 
fewer opportunities for exposure to HBV. 
Of course, the assumption that the 1 - 9 year old subjects who were tested 
were a random, non-biased sample may be incorrect. For example, one could suppose 
that some progeny infected by HBsAg-positive mothers were selectively excluded. 
Since only about 25 children were potentially involved on either Maiao or Hiva 
0a, if even one HBsAg-positive sibship of 3 -5 children was excluded it would 
have made a considerable difference in the prevalence rates. 
The second assumption, that the remaining numbers of untested individuals 
(25 on Hiva 0a and 27 on Maiao) were randomly distributed by age, could also 
have been incorrect. On Hiva 0a, and to a slightly lesser extent on Maiao, 
the actual number of subjects in the 20 - 29 year old age group was markedly 
lower than that in the two younger age deciles. If one corrects for the es¬ 
timated 25% loss of untested 1 - 9 year old subjects, this difference becomes 
even more remarkable and more difficult to explain. Was there a precipitous 
increase in the birth rate within the past 19 years? Was there increased 
mortality among those 20 - 29 years of age or^was there selective emmigration 
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or, was the sample biased to exclude selectively some of these persons from 
testing? The answers to these questions are not known. 
Another potential source of error to be considered is that HBV infection 
itself may have influenced the availability of subjects for testing, presumably 
because they would have been acutely ill from the disease and physically unable 
to come for venipuncture, or conversely, more likely to seek medical care, or 
because there was an HBV infection-associated increased mortality which selectively 
removed affected individuals. However, not one of the subjects examined on any of 
the four islands manifested clinical evidence of hepatitis. Furthermore, jaundice 
ascitis or "liver disease" were problems unheard of by the people of these islands. 
Clinical hepatitis is extremely rare even in the main hospital in Tahiti (to which 
the large Tahitian population has access and to which inhabitants of these outlying 
islands are evacuated in case of severe illness) where authorities cannot recall 
even a single case of fatal non-alcoholic liver disease, including hepatoma. 
Of course one cannot be certain whether extensive autopsies were performed in 
Tahiti and, even though the evacuation option (via radio link) exists on all in¬ 
habited islands of French Polynesia, one cannot know how many deaths of unknown 
cause actually occur. Nevertheless, in the absence of any evidence of physical 
sequelae of HBV infection, it is hard to imagine in what ways HBV infection per se 
could have influenced either the inclusion or exclusion of subjects for this study. 
Finally, how might selection biases have been reflected in the 100 Maiao 
subjects tested in both 1978 and 1980 (about 50% [100/206] of the inhabitants)? 
The distribution of subjects by age group was very similar from year to year 
except perhaps for the 10-19 year old group where there were 28% more subjects 
(six males and four females) in 1980 (46 vs. 36). However, the HBsAg, anti-HBs and 
total infection (94% vs 98%) rates were remarkably similar in both years and it 
is therefore likely that, in both 1978 and in 1980, the persons in the 10-19 
year old age group were representative of the population at large. 
. 
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Another difference between 1978 and 1980 was that 93% of males and 83% of 
females were infected in 1978, compared to 95% and 93% respectively, in 1980. 
Both a relative (55% vs. 84%) and absolute (12 vs. 16) increase in the number 
of infected 1 - 9 year olds in 1980 was the main contributing factor. This 
was consistent with the previously discussed possibility thata biased sample 
of children in this age group was obtained. Another possible cause was that 
these differences reflected a real, even if transient, change in the prevalence 
of acute HBV infection from one year to the other, especially since this was 
the age group which contained the greatest number of susceptible individuals 
and seroconverters. One cannot be certain which was the case. 
Looking only at those 100 individuals tested in both 1978 and in 1980 
(Table 11), the distribution of infected persons was very similar to that of 
the entire 1978 and 1980 samples. Therefore, the calculation of HBV incidence 
which was based on this sample is likely to reflect the true incidence among those 
susceptible persons in the two larger samples. And to the extent that these 
samples were representative of the entire island population, the calculated 
55% to yearly incidence among susceptibles represented the true incidence of HBV 
infection on Maiao. The numbers of subjects within each age group was felt to 
be too small to make meaningful calculations of age-specific incidence. 
HBsAg prevalence and the chronic carrier state 
In the longitudinally followed sample from Maiao (Table 12), 19/20 (95%) 
of individuals with HBsAg were chronic carriers of the antigen. The person who 
lost HBsAg was a 33 year old female who had only anti-HBc in 1980. She was either 
resolving her infection and beginning to make anti-HBs or still had undetectably 
low HBsAg levels. Furthermore, they represented 19% of subjects tested which 
was almost identical to the 20% of subjects found to be HBsAg-positive in the 
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entire 1978 subject pool (Table 7). This strongly suggests that over 90%, 
perhaps closer to 100%, of HBsAg-positive subjects on Maiao (when tested on a 
single occasion) were actually chronic carriers of HBsAg and is an assumption 
similar to that derived from many other studies of populations with high HBV 
infection rates (e.g., 81, 116, 120, 137). 
The HBsAg prevalence on Maiao was 24% among males, 15% among females and 
20% overall. In both sexes it rose to a peak in the 30 - 39 year old age group 
and declined thereafter. This sex distribution pattern is very similar to that 
noted in other South Pacific studies (6, 15, 17, 41-43, 81). The peak age 
prevalence occurred in an age group 10 - 20 years older than has been reported 
in some studies (40-42) in which assay techniques of similar sensitivity to ours 
were used, although it was similar to that found in another (81). Similarly, 
infection prevalence (HBsAg plus anti-HBs plus anti-HBc) was higher in males 
than in females, as has also been found elsewhere (6, 15, 17, 41-43, 81). Again, 
these differences were not tested by statistical methods due to the unknown effects 
of possible selection biases. 
Mazzur and Jones compared the ratio of surface antigenemia to that of anti¬ 
body in a Melanesian population (81) and found it to be significantly higher in 
the population under six years of age (the group which also had the highest HBsAg 
prevalence). This they took as an indication that children below six years tended 
to become chronic carriers rather than produce antibody. The HBsAg to anti-HBs 
ratio on Maiao (in 1978 and on the paired samples) rose from 0.54 in the 1 - 9 
year old group to 1.0 in the 30 - 39 year old group and quickly decreased thereafter. 
This is a similar pattern to that found by Mazzur and Jones although the Maiao 
peak occurs at a different age. However, they did not measure anti-HBc, the presence 
of which, at least in the older age groups, may well indicate low level carrier 
state (53). Adding these values to the numerator of the antigen/antibody ratios 
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shows that while they still peak in the 30 - 39 year old group, they also remain 
high thereafter. Thus, for Maiao one cannot conclude on this basis that younger 
persons tend to become antigen carriers while older persons tend to make anti¬ 
body when infected. While anti-HBc prevalence on Hiva 0a was merely 2%, the 
HBsAg/anti-HBs ratio was very similar to that on Maiao with a peak at 30 - 39 
years of age. 
The situation on Hiva 0a appeared to be different from that on Maiao. Al¬ 
though the combined HBsAg prevalence was 20% as on Maiao, it was greater in 
females (24%) than males (16%) overall and in almost all age groups. Further, 
only two (2%) individuals without HBsAg or anti-HBs had anti-HBc,versus 16 (10%) 
on Maiao. On Hiva 0a, those persons with anti-HBc were in the 1-19 year old 
age groups (suggesting acute infection) whereas they were seen to become increas¬ 
ingly corronon with age (in both sexes) on Maiao, paralleling gradual decreases in 
HBsAg prevalence (suggesting they might have been long-time chronic carriers 
of low-level HBsAg [Table 2]).. Anti-HBs was nearly equally common tn all ages 
in both sexes within each island but was slightly less prevalent on Hiva 0a 
(50%) than on Maiao (58%). This was in keeping with the lower combined overall 
infection rate of 70% on Hiva 0a as compared with 88% on Maiao. 
Sixty-eight percent of the Hiva 0a population had either HBsAg or anti-HBs 
compared to 78% on Maiao. Two of the remaining 38 individuals (5%) on Hiva 0a 
compared to 16 of 34 (47%) on Maiao had anti-HBc only. Keeping in mind that 
anti-HBc prevalence increased with age on Maiao, this observation suggests that 
there were fewer chronic carriers on Hiva 0a than on Maiao. If this was indeed 
the case, then the 20% of persons on Hiva 0a with HBsAg could not be indentified 
with certainty as chronic carriers. The longitudinal data which would resolve 
this issue are unfortunately lacking for Hiva 0a. However, if these persons 
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were not chronic carriers then the Hiva Oa population would be unlike many 
studied elsewhere in the South Pacific and this could account for the unusual 
age and sex distributions of infection that were found. This could be due to 
environmental features not readily apparent or to genetic influences. 
Rapa and Mangareva 
Data from Rapa and Mangareva are difficult to interpret since a relatively 
small portion of the inhabitants were tested. Nevertheless, Rapa is especially 
intriguing (Table 8) because the age and sex prevalence of HBsAg, while similar 
in pattern to that reported eleswhere and found on Maiao, was of a 
much greater magnitude.. If all of the untested Rapa inhabitants had had 
HBsAg, the HBsAg prevalence would have increased from 58% to 81% and if none 
had HBsAg, would have decreased to 25%, still a remarkable figure when compared 
to other studies of South Pacific populations (Table 4). But with a minimum 
of 25% of the population infective and with a minimum of 42% (168/398) already 
infected, it is unlikely that very many of the untested individuals had in fact 
escaped infection. For example, on Maiao and Hiva Oa, where only 20% of the popu¬ 
lation had HBsAg, at least 65% (134/206) and 49% (84/170) respectively of the 
entire populations were infected (again, assuming that none of the untested in¬ 
habitants were infected, which is the least likely assumption). 
Mangareva (Table 9) had the lowest HBsAg prevalence of all four islands (4%) 
as well as the lowest overall infection rate (36%), although anti-HBc determinations 
were not included in these calculations. It is doubtful that the tested subjects 
were randomly distributed since the number in each age group varied considerably 
and there was a notable paucity of subjects in the 1 - 9 year old group. 

55 
HBeAg and Anti-HBe 
HBeAg and anti-HBe determinations were made using an agar gel immunodiffusion 
assay (69), which is capable of picking up only relatively high concentrations 
of antigen or antibody. It is therefore likely that a significant number of the 
double-negative results recorded were false negative results. Fifty-six percent 
of the samples contained neither HBeAg nor anti-HBe (Table 13). 
HBeAg and anti-HBe have been measured among HBsAg-positive Micronesians (41) 
and Polynesians (40). HBeAg prevalence (by RIA) was 11% (no anti-HBe) among 
Micronesians and 38% (1% anti-HBe) in Polynesians. 
Other studies (92, 114) have suggested that HBeAg decreases while anti-HBe 
increases with age among HBsAg-positive subjects. Again, because of the relative 
insensitivity of the agar-gel immunodiffusion assay compared with RIA, it is inap¬ 
propriate to compare our results (Table 13) either in total or by age and sex 
with those obtained elsewhere in the Pacific. 
Because of the suggestion (84) that the presence of HBeAg is associated with 
increased infectivity, one might have expected to find a greater proportion of 
HBeAg on those islands where HBsAg prevalence was highest. Comparing Maiao to 
Hiva 0a, this was certainly the case (45% vs. 4%), but Rapa had 30% HBeAgposi+'we. 
This is surprising, because even in the least likely case that none of the un¬ 
tested inhabitants of Rapa had HBsAg, Rapa's HBsAg prevalence would still have 
been greater than Maiao's (25% vs. 20%). Perhaps the amount of HBeAg was different 
among Rapa samples and below the sensitivity of our assay. 
The Genetic Hypothesis 
Debates in the literature over the hypothesis that there is a genetic 
susceptibility to developing the HBsAg-positive chronic carrier state have 
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centered around whether one can invoke environmental factors and/or non-random 
contact-associated HBV transmission (7, 10, 82) to account equally well for ap¬ 
parent genetic segregation of carriers. In addition, some authors have purported 
to have disproved the hypothesis (80, 83, 117, 145) of autosomal recessive inheri¬ 
tance of susceptibility by finding that progeny of carrier fathers and mothers 
(both supposedly homozygous recessives) developed anti-HBs, not HBsAg, when 
infected. 
The genetic analysis carried out thusfar on Maiao does not resolve these 
issues. Although the patterns of HBsAg acquisition were found to be consistent 
with an autosomal recessive mode of inheritance of infection susceptibility, 
there was no family in the Maiao pedigrees in which both parents could be iden¬ 
tified as chronic carriers. 
In considering the operation of intrafami1ia1 spread of HBV infection, 
family C in figures 7 and 8 bears particular comment. The 30 year old mother (114) 
was a chronic carrier of HBsAg. In 1978, (figure 7) her 37 year old husband (106) 
was not infected and of the five offspring tested, four were likewise uninfected 
and one (107, 10 years old) had. anti HBs. We see that by 19 months later (figure 8), 
three of the four uninfected children and the husband had been acutely infected 
and had made HBsAg. Since these individuals had all presumably been exposed to 
other persons or environmental factors which transmitted HBV, in the same way 
as had the entire population, this observation suggests that intrafamilial spread 
of infection has occurred during the nineteen month observation period. Of the 
several families in which this mechanism might be expected to have operated e.g., 
families A, B and C in figures 5 and 6, this was the only one with susceptible 
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members which was witnessed during our sampling interval. That infection occurred 
more often in any nuclear family with an HBsAg-positive member than it did in 
other families was shown not to be statistically significant. It must be remem¬ 
bered, however, that only 56% of the Maiao inhabitants are shown on the pedigree 
and that only 32% were tested in both 1978 and 1980. With these limitations, it 
is still hard to avoid the conclusion that intrafamilial spread from HBsAg-positive 
individuals was occurring on Maiao. 
There was evidence that progeny of all ages, and 1 to 9 years old in particular, 
of mothers with HBsAg were more likely to have HBsAg themselves but that infection 
per se was not more likely. However, looking back at the pedigrees (figures 5 - 8), 
one sees that though statistically significant, these conclusions are in part 
based on only two families which had HBsAg-positive mothers, only one of whom 
could be identified for certain as a chronic carrier (family C, figures 7 and 8), 
The 1980 data are missing on mother 192 in family A, figures 5 and 6). Given this 
limitation, one can say only that the data are consistent with the operation of 
autosomal recessive inheritance of susceptibility to acquiring HBsAg. The addition 
of HLA phenotypes to the pedigrees may well resolve the issue of whether a genetic 
mechanism controls susceptibility to developing the chronic carrier state. 
It would be extremely interesting to repeat the Hiva 0a sample collection 
and to study the natural course of HBV infection over time, as was done on Maiao. 
It is possible that this would also provide an answer to the question of whether 
the inhabitants of Hiva 0a are reacting differently to HBV infection that people 
living on Maiao and elsewhere. 
A strong effort could be made to test those individuals on Maiao or Hiva 0a 
for whom blood serum samples or pedigree data were lacking. If this information 
were available, it would eliminate most sources of sample bias and could be used 
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in conjunction with HLA data to carry out a sophisticated, state-of-the-art 
analysis of the gentic susceptibility hypothesis which would go a long way 
towards resolving an issue that has been seriously debated for over twenty 
years. 
Regardless of how these genetic issues are finally resolved, it should 
be recognized that the inhabitants of these islands have the highest HBV 
infection rates which have ever been reported. This is a truly remarkable 
finding which begs more thorough investigation. Is there subclinical involve¬ 
ment of the liver? What are the specific environmental and immunologic factors 
which encourage transmission and maintenance of infection among these people? 
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Table 2. Interpretation of Serologic Markers of HBV Infection (from 53) 
Serologic Reactivity 
Interpretation Pattern HBsAg Anti-HBc Anti-HBs 
1 +- — ~ 






_ a. Acute viral hepatitis or 
b. Chronic HBsAg carrier state 
3 - + + 





a. (low titer) long after HBV 
infection 
b. (high titer) immediate con¬ 
valescence from HB of 
“low level” chronic carrier 
state 
5 - — + 
Long after HBV infection or 
immunization with HBsAg 
Table 3. Risk Factors in HBV Infections (from 126) 
A. Enhanced Probability of Exposure 
Blood transfusion and other parenteral procedures 




B. Enhanced Probability of HBsAg, Persistence 
Immune defects 




C. Both Enhanced Exposure and Persistence 
Birth to carrier-mothers 
Maintenance hemodialysis 














Caledonia Fiji Fiji I 
HBsAg 1.12 15% -13% 11% 9% 
Anti-HBc .88°; -. ----- 22% 
Anti-HBs- - 
- - 


















RACE Melane sian •lelanesian Melanesian lelanesian Melanesian Melanesian lelanesian Melanesian + 
Indian 
METHOD ID+ . RIA. ID IEOP PHA. rphA 


































* British Solomon Islands Protectorate + Please refer to Table 1 for an explan¬ 
ation of testing methods listed in this 
table. 
Table 4. Composite results of HBV survey studies carried out in the South 
Pacific. These data are generally based on random samples of a small propor¬ 
tion of an island's population. 
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Island - - 
New 
Hebrides Gi1bert Nauru EUice runafuti Niue Niue 
HBsAg 2% 26% 15% . . 8% 10% 5% 
Anti-HBc - ■ — - .. 




















RACE_ Micrpnesiar licrunesiar Micronesiar Polynesian Polynesian Polynsian Polynesian 

































Island Population No. % 
Rapa 398 (175) 44 
Mangareva* 468 (189) 40 
Hiva Oa + 170 (120) 71 
Maiao 1978 206 (152) 74 
Maiao 1980 198 (156) 79 
* Village of Rikitea 
+ Village of Atuona 
Table 5. Proportion of the populations 
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Figure 2. The serologic responses of an individual with a 
transient HBsAg response after exposure to HBs-Ag positive serum. 
From: Maxcy-Robinson Public Health and Preventative Medicine» 
by OH Last (67) 
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Figure 3. Serologic responses of an individual 
who developed the HBs-Ag positive chronic carrier 
state. From Hoofnagle et al, 1978 ( 53 ). 
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